Zogenix, Inc. and Desitin Pharmaceuticals GmbH Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom

SAN DIEGO and HAMBURG, Germany, Jan. 6, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") today announced that the Federal Institute for Drugs and Medical Devices of Germany (BrArM), and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) have approved the Marketing Authorization Application (MAA) for SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache.